Sign In
Buy VYGR
$3.60
+0.0100 (+0.279%)
At Close: Jun 03, 2026
argenx (ARGX) Up on Positive Autoimmune Disorder Study Data
12:42pm, Wednesday, 23'rd Mar 2022 Zacks Investment Research
argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.
Vertex (VRTX) to Begin Pivotal Study on Kidney Candidate
12:28pm, Wednesday, 23'rd Mar 2022 Zacks Investment Research
Vertex's (VRTX) pivotal phase III study on VX-147 targeting a broad patient population with proteinuric kidney disease mediated by two mutations in the APOL1 gene (AMKD) is expected to begin later thi
Pfizer and Novartis Are Betting On This Under-the-Radar Biotech. Should You?
10:05am, Saturday, 19'th Mar 2022 The Motley Fool
Voyager Therapeutics has promising technology. But the stock is very risky.
Pfizer and Novartis Are Betting On This Under-the-Radar Biotech. Should You?
06:05am, Saturday, 19'th Mar 2022
Voyager Therapeutics has promising technology. But the stock is very risky.
Voyager Therapeutics (VYGR) Surges 12.1%: Is This an Indication of Further Gains?
01:47pm, Thursday, 17'th Mar 2022 Zacks Investment Research
Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mor
Voyager Therapeutics (VYGR) Surges 12.1%: Is This an Indication of Further Gains?
11:17am, Thursday, 17'th Mar 2022
Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mor
AstraZeneca's (AZN) Fasenra sBLA for Nasal Polyps Gets CRL
03:13pm, Tuesday, 15'th Mar 2022 Zacks Investment Research
The FDA gives CRL to AstraZeneca's (AZN) sBLA for Fasenra for chronic rhinosinusitis with nasal polyps (CRSwNP) for want of additional clinical
AstraZeneca (AZN) Stock Up 27% in a Year: What Lies Ahead?
02:52pm, Tuesday, 15'th Mar 2022 Zacks Investment Research
AstraZeneca's (AZN) stock has risen 26.9% in the past year compared with an increase of 22.3% for the industry.
After Golden Cross, Voyager Therapeutics (VYGR)'s Technical Outlook is Bright
11:18am, Tuesday, 15'th Mar 2022
Is it a good or bad thing when a stock experiences a golden cross technical event?
Novartis (NVS) Announces Data on Zolgensma, Acquires Coalesce
04:18pm, Monday, 14'th Mar 2022 Zacks Investment Research
Novartis (NVS) reports positive data on SMA treatment from a phase III study. It also acquires Coalesce Product Development Limited to strengthen its respiratory and complex generics business.
The Zacks Analyst Blog Highlights Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences
05:27pm, Thursday, 10'th Mar 2022 Zacks Investment Research
Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences are included in this blog.
Biotech Stock Roundup: OCGN Down on Update, VYGR Surges on Deal & Other Updates
05:54pm, Wednesday, 09'th Mar 2022 Zacks Investment Research
Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.
Voyager (VYGR) Gains on Deal With Novartis for Gene Therapies
05:35pm, Wednesday, 09'th Mar 2022 Zacks Investment Research
Voyager (VYGR) stock rises on the license option agreement with Novartis to get a target-specific access to next-generation TRACER AAV capsids for gene therapy programs.
Novartis and Voyager Therapeutics reach licence option agreement for next-generation gene therapy vectors for neurological diseases - Express Pharma
08:33am, Wednesday, 09'th Mar 2022 Express Pharma
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Novartis and Voyager Therapeutics reach licence option agreement for next-generation gene therapy vectors for neurological diseases
08:33am, Wednesday, 09'th Mar 2022 Express Pharma
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders The post Novartis and Voyager Therapeutics reach licence option agreement for next-generation gene therapy vectors for neurological diseases appeared first on Express Pharma .
